Jukka Westermarck

CIP2A-promoted astrogliosis induces AD-like synaptic degeneration and cognitive deficits (2019)

Neurobiology of Aging

Shentu Y-P., Hu W.T., Zhang Q., Huo Y.D., Liang J.W., Liuyang Z-Y., Zhou H., Wei H., Ke D., Wang X.C., Wang J.Z., Man H.Y., Westermarck J., Liu R.

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Combined inhibition of tumor suppressors PTEN and PP2A drives anoikis resistance and is associated with therapy relapse in prostate cancer (2019)

American Association for Cancer Research Annual Meeting 2019, Cancer Research

Rupp C, Isomursu A, Aakula A, Erickson A, Li SP, Kaur A, Shah P, Pokharel YR, Trottman L, Lammerding J, Rannikko A, Taimen P, Mirtti T, Paatero I, Ivaska J, Westermarck JK

(Muu (O2))

Arpp19 Promotes Myc and Cip2a Expression and Associates with Patient Relapse in Acute Myeloid Leukemia (2019)

Cancers

Mäkelä E, Löyttyniemi E, Salmenniemi U, Kauko O, Varila T, Kairisto V, Itälä-Remes M, Westermarck J

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Enhanced expression of MycN/CIP2A drives neural crest toward a neural stem cell-like fate: Implications for priming of neuroblastoma (2018)

Proceedings of the National Academy of Sciences of the United States of America

Kerosuo L, Neppala P, Hsin J, Mohlin S, Vieceli FM, Torok Z, Laine A, Westermarck J, Bronner ME

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer (2018)

International Journal of Biochemistry and Cell Biology

Otto Kauko, Jukka Westermarck

(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))

Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer (2018)

Cancer Medicine

Eva-Maria Birkman, Adam Elzagheid, Terhi Jokilehto, Tuulia Avoranta, Eija Korkeila, Jarmo Kulmala, Kari Syrjänen, Jukka Westermarck, Jari Sundström

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells (2018)

Science Translational Medicine

Otto Kauko, Caitlin M. O’Connor, Evgeny Kulesskiy, Jaya Sangodkar, Anna Aakula, Sudeh Izadmehr, Laxman Yetukuri, Bhagwan Yadav, Artur Padzik, Teemu Daniel Laajala, Pekka Haapaniemi, Majid Momeny, Taru Varila, Michael Ohlmeyer, Tero Aittokallio, Krister Wennerberg, Goutham Narla, Jukka Westermarck

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer's Disease (2018)

Cell Reports

Yang-Ping Shentu, Yuda Huo, Xiao-Long Feng, James Gilbert, Qing Zhang, Zhen-Yu Liuyang, Xiu-Lian Wang, Guan Wang, Huan Zhou, Xiao-Chuan Wang, Jian-Zhi Wang, You-Ming Lu, Jukka Westermarck, Heng-Ye Man, Rong Liu

(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))

Phosphatases catching up with the level of knowledge: Finally druggable? (2018)

International Journal of Biochemistry and Cell Biology

Jukka Westermarck

(Kirjoitus tai data-artikkeli tieteellisessä aikakauslehdessä (B1))

Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back (2018)

FEBS Journal

Jukka Westermarck

(Kirjoitus tai data-artikkeli tieteellisessä aikakauslehdessä (B1))

Ota yhteyttä

Linkit

Julkaisut

Järjestä:

CIP2A-promoted astrogliosis induces AD-like synaptic degeneration and cognitive deficits (2019)

Combined inhibition of tumor suppressors PTEN and PP2A drives anoikis resistance and is associated with therapy relapse in prostate cancer (2019)

Arpp19 Promotes Myc and Cip2a Expression and Associates with Patient Relapse in Acute Myeloid Leukemia (2019)

Enhanced expression of MycN/CIP2A drives neural crest toward a neural stem cell-like fate: Implications for priming of neuroblastoma (2018)

Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer (2018)

Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer (2018)

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells (2018)

CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer's Disease (2018)

Phosphatases catching up with the level of knowledge: Finally druggable? (2018)

Targeted therapies don't work for a reason; the neglected tumor suppressor phosphatase PP2A strikes back (2018)